Showing 2623 results
- https://www.novartis.com/news/media-releases/gilenya-data-aan-highlight-novartis-leadership-innovation-new-ms-assessment-methods-benefit-patients-and-physiciansNew analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
- https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenutm-simplify-treatment-administration-patients-chronic-iron-overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment…
- https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-leading-antifungal-agent-mycamine-from-astellas-reinforcing-leading-global-anti-infectives-portfolioSandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly…
- https://www.novartis.com/news/media-releases/novartis-accelerates-cancer-immunotherapy-efforts-aduro-biotech-alliance-and-launch-new-immuno-oncology-research-groupCollaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
- https://www.novartis.com/news/media-releases/novartis-cosentyxtm-two-year-data-shows-sustained-effect-and-favorable-safety-profile-psoriasis-patientsAfter two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
- https://www.novartis.com/news/media-releases/new-novartis-data-shows-cosentyxtm-significantly-superior-stelara-and-clears-skin-pasi-90-nearly-80-psoriasis-patientsCLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
- https://www.novartis.com/news/media-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-yearsResults from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six…
- https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-jakavi-polycythemia-vera-first-targeted-therapy-approved-patients-rare-blood-cancerJakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
- https://www.novartis.com/news/media-releases/novartis-present-new-late-breaking-cosentyxtm-data-aad-2015-showing-significant-patient-benefit-achieving-clear-skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
- https://www.novartis.com/news/media-releases/fda-approves-first-biosimilar-zarxiotm-filgrastim-sndz-from-sandozSandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page